CASTRATION-RESISTANT PROSTATE CARCINOMA
Clinical trials for CASTRATION-RESISTANT PROSTATE CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new CASTRATION-RESISTANT PROSTATE CARCINOMA trials appear
Sign up with your email to follow new studies for CASTRATION-RESISTANT PROSTATE CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Experimental drug targets Hard-to-Treat prostate cancer in bone
Disease control TerminatedThis study tested the drug erdafitinib in 11 men with advanced prostate cancer that kept growing despite hormone therapy and had spread to the bones. The goal was to see if erdafitinib could help control the cancer by blocking certain growth signals. Researchers also looked at bl…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 05:05 UTC
-
New combo aims to outsmart Drug-Resistant prostate cancer
Disease control TerminatedThis early-phase trial tested whether adding decitabine/cedazuridine to enzalutamide could help men with metastatic castration-resistant prostate cancer whose cancer had stopped responding to enzalutamide alone. Only 8 men participated before the study was stopped. The main goals…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 26, 2026 05:05 UTC
-
Promising combo for tough prostate cancer hits roadblock
Disease control TerminatedThis study looked at adding a new drug, ribociclib, to standard hormone therapy (enzalutamide) for men with advanced prostate cancer that had spread and stopped responding to hormone treatment. The goal was to find a safe dose and see if the combination could lower PSA levels. Th…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
Promising combo for tough prostate cancer hits snag, study halted
Disease control TerminatedThis study tested a combination of two drugs, apalutamide and abiraterone, along with prednisone, in men with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The goal was to see if this drug combo could slow cancer growth. Only 7 people enr…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 19, 2026 11:48 UTC
-
New PET scan aims to spot hidden prostate cancer
Diagnosis TerminatedThis study tested a special PET scan using a new imaging agent called 68Ga-PSMA-11 to get clearer pictures of prostate cancer that has spread in the body. It involved 15 men with advanced prostate cancer that no longer responds to hormone therapy. The goal was to see if this scan…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: Thomas Hope • Aim: Diagnosis
Last updated May 20, 2026 11:55 UTC
-
Bone pain trial halted after enrolling only one patient
Symptom relief TerminatedThis study tested a radioactive drug called Sn-117m-DTPA to see if it could reduce bone pain in men with prostate cancer that had spread to their bones. Only one person enrolled before the study was stopped early. The goal was to measure pain relief over several weeks, but no con…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Symptom relief
Last updated May 19, 2026 12:00 UTC